Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06630234 · ClinicalTrials.gov registry record · Phase 1
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
A Phase 1 study of Gastrointestinal Stromal Tumor (GIST), sponsored by Deciphera Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 10
- Study locations
NCT06630234: Recruiting Phase 1 study of Gastrointestinal Stromal Tumor (GIST), sponsored by Deciphera Pharmaceuticals.
NCT06630234 is a Phase 1 study of Gastrointestinal Stromal Tumor (GIST) that is actively recruiting participants, run by Deciphera Pharmaceuticals. The registered enrollment target is 120 participants, below the 174-participant average among 6 other Gastrointestinal Stromal Tumor (GIST) trials with a reported enrollment target (31% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06630234, a Phase 1 study of Gastrointestinal Stromal Tumor (GIST), is actively recruiting participants, sponsored by Deciphera Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer therapies. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). Participants will be treated in 28-day treatment cycles with an estimated duration of up to 2 years.
Primary Outcome
DLTs assessed for each dose level.
Conditions Studied
Interventions
- DRUG DCC-3009
Study Locations (10)
Florida
- Mayo Clinic Florida - Jacksonville
- University of Miami - Sylvester Comprehensive Cancer Center - Miami
Arizona
- HonorHealth - Scottsdate
California
- UC San Diego Moores Cancer Center - La Jolla
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- START Midwest - Grand Rapids
Minnesota
- Mayo Clinic Rochester - Rochester
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-12-10 |
| Est. Completion | 2028-05 |
| Phase | Phase 1 |
What NCT06630234 shows while recruiting
NCT06630234 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 174-participant average among 6 other Gastrointestinal Stromal Tumor (GIST) trials with a reported enrollment target (31% lower).
The record links to 1 condition, with Gastrointestinal Stromal Tumor (GIST) appearing as the primary indexed condition, and to 1 intervention - of which DCC-3009 is the first listed.
NCT06630234 lists 10 locations in 9 states (Florida, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT06630234 about?
NCT06630234 is a clinical study titled "A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)". The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer...
What is the current status of trial NCT06630234?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2024-12-10. Estimated completion is 2028-05.
What conditions does trial NCT06630234 study?
This clinical trial studies the following conditions: Gastrointestinal Stromal Tumor (GIST).
What interventions are being tested in trial NCT06630234?
The interventions under investigation include: DCC-3009 (DRUG).
Who is sponsoring clinical trial NCT06630234?
This trial is sponsored by Deciphera Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06630234 being conducted?
This trial has 10 study locations across Arizona, California, Colorado, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Stromal Tumor (GIST)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
RECRUITING · Phase 1
-
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
RECRUITING · Phase 1
-
MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
ACTIVE NOT RECRUITING · Phase 1
-
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
RECRUITING
-
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
RECRUITING
-
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI